{
  "docId": "019de073-187a-71e9-a3c0-2f4159454068",
  "docSlug": "48ce63a07f3c546c39a71c96ea43409e",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 40,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Includes a detailed list of medical abbreviations in the footer.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-187a-71e9-a3c0-2f4159454068/20",
  "deckHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068",
  "deckJsonHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068.json",
  "deckAnchorHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.285,
        "y": 0.62
      },
      "kind": "list",
      "text": "eplontersen: ATTRv-PN (NEURO-TTransform) - Co-primary endpoints met in a planned interim analysis at 35 weeks; Statistically significant and clinically meaningful change on modified NIS+7, serum TTR concentration; Ongoing Phase III trial.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c125b000-6baf-43c1-90a8-551854a6a4f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.285,
        "y": 0.35
      },
      "kind": "list",
      "text": "Farxiga: HFpEF (DELIVER) - Statistically significant and clinically meaningful reduction in CV mortality, worsening HF; Efficacy in patients with HF with mildly reduced or preserved ejection fraction; Ongoing Phase IIb combination trials.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fdaf17c3-65fd-41d4-96d3-09c5623c3128",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.3,
        "x": 0.69,
        "y": 0.23
      },
      "kind": "list",
      "text": "H2 2022: Tezspire, nirsevimab, Fasenra, AZD8233 news flow. 2023: Farxiga, eplontersen, Fasenra, Farxiga news flow.",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02c981e2-ba31-4eeb-a826-f424e8e5af75",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.285,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Abbreviations: LVEF, HF, CKD, ATTR-PN, TTR, NIS+7, RSV, HFpEF, EPGA, HES, MI, EOE, LRTI.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26b2a1ca-0d7d-42a3-845e-9830f28c02e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.6,
        "x": 0.318,
        "y": 0.135
      },
      "kind": "title",
      "text": "Positive Phase III trial results for Farxiga, eplontersen",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1494b1fa-c3ea-4421-98a9-9645ade4caf5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.485,
        "x": 0.318,
        "y": 0.065
      },
      "kind": "title",
      "text": "BioPharmaceuticals: Q2 2022 R&D",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39a8dfd7-8f7e-43f0-a540-1a93b9c8cd44",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "3a935794-0e8a-4d64-a34d-ca1f2e57bb4b",
      "evidence": "list/bullet: Farxiga: HFpEF (DELIVER) - Statistically significant and clinically meaningful reduction in CV mortality, worsening HF; Efficacy in patients with HF with mildly reduced or preserved ejection fraction; Ongoing",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}